Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pilot Study Of Redirected Autologous T Cells Engineered To Contain an Anti-BCMA scFv Coupled To TCRζ And 4-1BB Signaling Domains in Patients With Relapsed and/or Refractory Multiple Myeloma

Trial Profile

Pilot Study Of Redirected Autologous T Cells Engineered To Contain an Anti-BCMA scFv Coupled To TCRζ And 4-1BB Signaling Domains in Patients With Relapsed and/or Refractory Multiple Myeloma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Oct 2018

At a glance

  • Drugs MTV-273 (Primary) ; Cyclophosphamide
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Oct 2018 Planned End Date changed from 1 Sep 2018 to 1 Sep 2020.
    • 12 Oct 2018 Planned primary completion date changed from 1 Sep 2018 to 1 Sep 2019.
    • 24 Jan 2018 Planned End Date changed from 1 Sep 2019 to 1 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top